Alfaxan® as an Anaesthetic Agent for Total Intravenous Anaesthesia (TIVA): A Clinical Trial in Dogs in Urban and Remote Rural Settings
World Small Animal Veterinary Association World Congress Proceedings, 2007
E.M. Tudor1; L.A. White2; B. O'Hagan3; T. Whittem3
1University of Melbourne; 2Frankston Heights Veterinary Clinic; 3Jurox Pty Ltd, Rutherford, Australia

The anaesthetic induction agent Alfaxan® has not previously been evaluated for induction and maintenance of anaesthesia by constant infusion (TIVA).

This study was designed to evaluate the efficacy and safety of Alfaxan® in a TIVA protocol in dogs.

Two cohorts of dogs were enrolled. The first was dogs being surgically desexed in a field setting in a remote aboriginal community. Following premedication with a premixed acepromazine, atropine and buprenorphine solution, anaesthesia was induced with Alfaxan, 2mg/kg administered intravenously over 60 seconds, and maintained by intravenous infusion using a syringe pump at a target rate of 7mg/kg. Dogs were intubated and spontaneously ventilated ambient air.

The second was enrolled at a suburban veterinary practice. Following similar premedication, the same Alfaxan TIVA protocol was used. Dogs were intubated, connected to an anaesthetic circuit and spontaneously ventilated 100% oxygen.

Induction, Anaesthetic Effectiveness and Recovery Scores were allocated using a previously described scoring system. ETCO2 (mmHg), SpO2 (%), heart rate, and respiratory rate were monitored throughout.

Average Induction, Anaesthetic Effectiveness and Recovery Scores were similar in both cohorts, with values correlating to acceptable for induction (3) and effectiveness (2.7) and good for recovery (3.2).

Physiological parameters were maintained within an acceptable range in all but two dogs in the suburban cohort, where apnoea and hypercapnia sufficient to warrant short periods of mechanical ventilation occurred.

Whilst supplemental oxygen should always be available, the findings suggest that an Alfaxan TIVA protocol provided acceptable cardiovascular, blood gas and respiratory parameters in dogs regardless of whether supplemental oxygen was administered.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Elizabeth Tudor
Veterinary Pharmacology Department of Pharmacology, University of Melbourne
Victoria, Australia


MAIN : Abstracts - Oral : Alfaxan Anesthetic
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27